NEW HAVEN, Conn., July 31, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced the pricing of its initial public offering of 5,625,000 shares of its common stock at a public offering price of $8.00 per share, before underwriting discounts. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "MRNS" on July 31, 2014. In addition, Marinus has granted the underwriters a 30-day option to purchase up to an additional 843,750 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on August 5, 2014, subject to customary closing conditions.
Stifel and JMP Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager and Janney Montgomery Scott is acting as co-manager for the offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.